David Cameron

David Cameron is a Senior Scientist at Debiopharm, where responsibilities include leading microbiology efforts on anti-infective programs from pre-clinical to phase II development since June 2022. Prior experience includes a role as a Scientific Researcher at Insel Gruppe, focusing on bacteriophages for treating multidrug-resistant infections and managing a laboratory team, from August 2018 to May 2022. David served as a Postdoctoral Research Fellow at Northeastern University's Antimicrobial Discovery Center, utilizing genome-wide screening to uncover antibiotic tolerance mechanisms and lecturing undergraduate microbiology, from January 2016 to July 2018. Earlier, David worked as a Postdoctoral Researcher at Monash University, defining antibiotic resistance mechanisms related to MRSA, and as a Medical Scientist at Gippsland Pathology Service. Academic qualifications include a PhD and a Bachelor of Science Honours from Monash University, emphasizing microbiology.